A Legacy of Pursuing a Better Way
Clinical Ink was founded in 2007 by the late Tommy Littlejohn, M.D., and current company president, Doug Pierce. Both passionately believed in revolutionizing data management to propel clinical research forward by eliminating paper source documentation — the last hurdle to paperless clinical trials.
Long before the iPad, Tommy and Doug envisioned an innovative tablet-based software application that would offer users the familiar look and feel of the paper source while allowing electronic capture, validation, and sharing for cleaner, faster data. Leveraging valuable perspectives and a unique mix of expertise, they paved the way for the future of clinical trials, launching Clinical Ink as a true pioneer in this essential industry transformation. Clinical Ink remains committed to dramatically reducing the cost and complexity of clinical research for sites, sponsors, and patients. The management team carries on Littlejohn and Pierce’s legacy by relentlessly pursuing a better way to deliver solutions that connect workflows and data.
Meet Our Management Team
Chief Executive Officer
Partner, NovaQuest Capital Management
Vern Davenport brings more than 30 years of executive experience in building and transforming healthcare technology and service companies. Before joining NovaQuest, Mr. Davenport was CEO and board member at Medfusion, a leader in healthcare consumerism technology where he was instrumental in the carve-out of the company from Intuit and the return of its core portal solution to a market leadership position. Operationally, he created a culture that earned a Best Places to Work award from Triangle Business Journal. In less than twelve months, the company developed and released two new products in patient payments and consumer patient record integration leveraging both cloud and mobile technologies.
Prior to Medfusion, Mr. Davenport was chairman and CEO of Medquist and leader in transcription services before and after the privatization of the company. As chairman and CEO, Mr. Davenport facilitated a transformation of the business through the acquisition of a speech technology company, rebranding the company M*Modal and leading the take private process that resulted in the sale of the business to One Equity Partners.
Partner, NovaQuest Capital Management
Michael Sorensen brings more than 15 years of investment experience and is a member of the Investment Committee at NovaQuest Private Equity. He is responsible for transaction origination, investment policy, fundraising, investor relations and the day-to-day management of NovaQuest Private Equity. In addition, he directs the private equity team in acquisitions, divestitures and oversight of portfolio companies.
Prior to NovaQuest, Mr. Sorensen was director at BlackRock’s private equity group, responsible for making investment decisions in a wide variety of geographies and industries, including healthcare, technology and consumer and retail, among others. He also held a variety of board seats while at the firm.
Managing Director, GI Partners
Dave Kreter is a managing director of GI Partners, with investment responsibilities for the company’s healthcare sector. Founded in 2001, GI Partners is a leading alternative investment management firm. It currently manages $2 billion dollars in capital commitments across multiple asset classes on behalf of highly respected institutional investors around the world. Mr. Kreter also serves on the boards of Generate Life Sciences, Netsmart Technologies, and GI's skilled nursing operator. Previously, he worked on investments in SoftLayer Technologies and the Telx Group, and served on the board of healthcare IT company Logibec and behavioral health provider AdvoServ.
Prior to joining GI Partners, he was with Francisco Partners in Menlo Park where he focused on private equity investments in the technology and healthcare industries, including the healthcare information technology (HCIT) business called Lynx Medical Systems. Earlier in his career, he worked in investment banking for Lehman Brothers' technology M&A group. Mr. Kreter holds an MBA from the Harvard Graduate School of Business and majored in economics for his undergraduate degree from Princeton University.
Vice President, GI Partners
Nathan Lipkin is a vice president at GI Partners. He currently serves on the board of Clinical Ink. Prior to rejoining GI Partners after business school, Mr. Lipkin was an investment banking analyst in the M&A group of Jefferies in New York.
Mr. Lipkin holds an MBA in healthcare management from the Wharton School of Business and a Bachelor of Science degree from the Medill School of Journalism at Northwestern University.
Vice President, Portfolio Operations, GI Partners
Connor McGauley is a vice president, portfolio operations, at GI Partners. He works with portfolio companies to accelerate growth and drives market diligence for potential investment. Mr. McGauley is on the boards of Clinical Ink and Blue Stream Fiber. Prior to joining GI Partners, he was the vice president of analytics and patient engagement for U.S. Anesthesia Partners, a Welsh, Carson, Anderson & Stowe portfolio company.
Prior to U.S. Anesthesia Partners, Mr. McGauley worked at Welsh, Carson, Anderson & Stowe, implementing best practice operating principles and continuous improvement programs across their portfolio of companies. Earlier in his career, he worked as a consultant across various industries including mining, financial services, and the public sector. Mr. McGauley holds a Bachelor of Commerce degree in accounting B.COMM from the University of British Columbia.
Independent Board Member/Advisor, Independent
Roman Margolin is an independent board member and advisor to healthcare and technology companies as well as an active angel/personal investor. Most recently, he was a managing director at Genstar Capital, one of the oldest private equity firms, managing approximately $20 billion of assets in software, healthcare, financial services, and industrial technology. At the firm for almost a decade, Mr. Margolin served on their investment committee and led their healthcare and technology practice. During his tenure, he led two of the largest realized investments in the firm’s history: ~$1 billion sale (4.4x return) of Netsmart and ~$2 billion dollar sale (8x return) of clinical trial technology company ERT. He was also a board member of PRA (Nasdaq: PRAH) and ConnectiveRx.
Prior to Genstar, Mr. Margolin co-founded a software startup incubated at Lightspeed Venture Partners. He was also an investment banker with JPMorgan and Brown Gibbons Lang, where he began his career two decades ago. He earned a bachelor’s in economics from Case Western Reserve University and an MBA from Stanford.
Independent Board Member/Advisor
Dawn brings a wealth of strategic leadership experience, having worked extensively within the healthcare industry, holding roles such as president, COO, and global managing director for several global healthcare companies. Currently the CEO of ProPharma Group, Dawn was formerly president of EnvisionRxOptions, a national, full-service pharmacy benefit management company. Dawn was responsible for strategy, product development, pricing, client analytics, IT, manufacturer and provider relations, marketing, and customer service operations. She also led all integration efforts for the acquisition of EnvisionRxOptions by Rite Aid in June 2015.
Dawn also served as COO for Teva Pharmaceuticals Europe, B.V., where she oversaw commercial operations across 36 countries and held global responsibility for patient solutions. Before joining Teva, she was COO of Medco International, B.V., where she focused on delivering innovative, integrated clinical services to improve efficiency across the European healthcare system. Prior to Medco, Dawn was global managing director for Hay Group Insight, the company’s survey research division. She worked with executive management teams and board members from Fortune 100 companies in a wide spectrum of industries to improve organizational and operational effectiveness.
Joseph Avellone, M.D.
Independent Board Member/Advisor
Dr. Avellone is a retired healthcare executive who serves on the boards of companies devoted to bringing new medicines to patients. Currently, he is on the board of directors of Apnimed, Clinical Ink, Celerion, and Immunity Health. He has previously served on the board of Cytel.
Prior to that, Dr. Avellone was on the executive management team of Parexel International, where he was responsible for global management of Parexel’s early phase, Phase II-IV, medical affairs, and clinical logistics services business units. His responsibilities included the oversight of all aspects of clinical trial conduct throughout the Americas, Europe, Africa, and Asia/Pacific regions. Before joining Parexel, Dr. Avellone was chief executive officer of Veritas Medicine, a healthcare technology company supporting clinical trials. He also previously served as chief operating officer of BlueCross BlueShield of Massachusetts.
Dr. Avellone is a fellow of the American College of Surgeons. He received his M.D. from Harvard Medical School and completed his general surgery residency at Brigham and Women’s Hospital. He also received a master’s in public administration from the John F. Kennedy School of Government at Harvard University, and a Bachelor of Arts from Dartmouth College.